Compare · ORKA vs QCLS
ORKA vs QCLS
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.86B, about 130.1x QCLS ($29.7M).
- Over the past year, ORKA is up 409.4% and QCLS is down 77.3% - ORKA leads by 486.7 points.
- ORKA has hit the wire 11 times in the past 4 weeks while QCLS has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for QCLS).
PerformanceORKA+409.39%QCLS-77.34%
2025-06-09+0.00%2026-06-08
- Company
- Oruka Therapeutics Inc.
- Q/C Technologies Inc.
- Price
- $64.03+6.51%
- $3.80+4.11%
- Market cap
- $3.86B
- $29.7M
- 1M return
- +0.02%
- +0.93%
- 1Y return
- +409.39%
- -77.34%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 0
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
Latest QCLS
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Director Voss Chelsea Sierra bought $5,522 worth of shares (1,753 units at $3.15) (SEC Form 4)
- Amendment: SEC Form 10-K/A filed by Q/C Technologies Inc.
- SEC Form 4 filed by White Billy Joe
- SEC Form 4 filed by Friscia Stephen
- SEC Form 4 filed by Voss Chelsea Sierra
- SEC Form 4 filed by Bernstein Bruce
- SEC Form 4 filed by Glass Mitchell
- SEC Form 4 filed by Silverman Joshua
- SEC Form 10-K filed by Q/C Technologies Inc.